A Prospective Study of Application of Platelet Mapping in HBV-related Acute-on-chronic-liver Failure in China

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03281278

Enrollment

100

Registered

2017-09-13

Start date

2017-10-30

Completion date

2018-08-13

Last updated

2019-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombelastography,Acute on Chronic Liver Failure, Platelet

Keywords

Thrombelastography,acute on chronic liver failure, platelet

Brief summary

Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. And through the platelet mapping, it can help provide a picture of patients' function of platelet. This study aims to explore the predictive role of platelet mapping in ACLF prognosis, organ failure developments and short term mortality.

Interventions

OTHERstandard treatment

standard medical treatment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patient with previously diagnosed or undiagnosed HBV related chronic liver disease/cirrhosis * INR≥1.5 and total bilirubin≥85μmol/L

Exclusion criteria

* INR≤1.5 or total bilirubin≤85μmol/L; * underlying chronic liver disease was other than chronic HBV infection related; * those who had hepatocellular carcinoma or other types of malignancies; * obstructive biliary diseases or other disease lead to bilirubin evaluation; * those who had acute hemorrhage one week before admission * those who received platelet, cryo transfusion or plasmapheresis one week before admission * using steroid or immunosuppressant or antiplatelet or anticoagulant drugs in 4 weeks * any kind of decompensation which persisted over a month * pregnancy and breastfeeding * those who received liver transplantation or kidney transplantation; * combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure（PaO2\<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS\<8) * readmission; * death within 24 hours.

Design outcomes

Primary

Measure	Time frame	Description
28-day mortality	28-day	death within 28-day

Secondary

Measure	Time frame	Description
28-day progression	28-day	progressed to EASL defined ACLF
90-day mortality	90-day	death within 90-day

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026